Clinical Report: Advancing Global Access: Addressing Inequities in Monoclonal Antibody Availability
Background
Monoclonal antibodies have revolutionized treatment in various diseases, yet access remains limited, especially in LMICs where billions lack these life-saving therapies. The disparity is stark, with only 16 mAbs listed on the WHO Essential Medicines List despite over 130 approved in high-income countries.
Data Highlights
mAb
Indication
Global Need (metric tons)
Nirsevimab
RSV prevention
7-14
WHO Essential Medicines List mAbs
Cancer and autoimmune diseases
23
Key Findings
Monoclonal antibodies are approved in high-income countries but largely inaccessible in LMICs.
Nirsevimab is a WHO-recommended long-acting mAb for RSV prevention.
Current access issues are driven by high manufacturing costs and fragmented disease-specific approaches.
Political mobilization has previously reduced costs of therapies, as seen with HIV antiretroviral treatments.
Clinical Implications
Healthcare providers should be aware of the disparities in mAb access.
Conclusion
Addressing the inequities in monoclonal antibody access is essential for improving health outcomes globally.
